221 related articles for article (PubMed ID: 31930715)
1. Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor.
Liva SG; Tseng YC; Dauki AM; Sovic MG; Vu T; Henderson SE; Kuo YC; Benedict JA; Zhang X; Remaily BC; Kulp SK; Campbell M; Bekaii-Saab T; Phelps MA; Chen CS; Coss CC
EMBO Mol Med; 2020 Feb; 12(2):e9910. PubMed ID: 31930715
[TBL] [Abstract][Full Text] [Related]
2. Enobosarm (GTx-024) Modulates Adult Skeletal Muscle Mass Independently of the Androgen Receptor in the Satellite Cell Lineage.
Dubois V; Simitsidellis I; Laurent MR; Jardi F; Saunders PT; Vanderschueren D; Claessens F
Endocrinology; 2015 Dec; 156(12):4522-33. PubMed ID: 26393303
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia.
Tseng YC; Kulp SK; Lai IL; Hsu EC; He WA; Frankhouser DE; Yan PS; Mo X; Bloomston M; Lesinski GB; Marcucci G; Guttridge DC; Bekaii-Saab T; Chen CS
J Natl Cancer Inst; 2015 Dec; 107(12):djv274. PubMed ID: 26464423
[TBL] [Abstract][Full Text] [Related]
4. Enobosarm (GTx-024, S-22): a potential treatment for cachexia.
Srinath R; Dobs A
Future Oncol; 2014 Feb; 10(2):187-94. PubMed ID: 24490605
[TBL] [Abstract][Full Text] [Related]
5. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
6. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT; Taylor RP; Mohler ML; Steiner MS
Curr Opin Support Palliat Care; 2013 Dec; 7(4):345-51. PubMed ID: 24189892
[TBL] [Abstract][Full Text] [Related]
7. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle.
Hardee JP; Counts BR; Gao S; VanderVeen BN; Fix DK; Koh HJ; Carson JA
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):369-383. PubMed ID: 29215198
[TBL] [Abstract][Full Text] [Related]
9. Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.
Morimoto M; Amano Y; Oka M; Harada A; Fujita H; Hikichi Y; Tozawa R; Yamaoka M; Hara T
PLoS One; 2017; 12(12):e0189480. PubMed ID: 29216311
[TBL] [Abstract][Full Text] [Related]
10. Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.
Morimoto M; Aikawa K; Hara T; Yamaoka M
Oncol Lett; 2017 Dec; 14(6):8066-8071. PubMed ID: 29344250
[TBL] [Abstract][Full Text] [Related]
11. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.
Ponnusamy S; Sullivan RD; You D; Zafar N; He Yang C; Thiyagarajan T; Johnson DL; Barrett ML; Koehler NJ; Star M; Stephenson EJ; Bridges D; Cormier SA; Pfeffer LM; Narayanan R
Hum Mol Genet; 2017 Jul; 26(13):2526-2540. PubMed ID: 28453658
[TBL] [Abstract][Full Text] [Related]
14. Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia.
Bora V; Patel D; Johar K; Goyal RK; Patel BM
Can J Physiol Pharmacol; 2022 Mar; 100(3):240-251. PubMed ID: 34614370
[TBL] [Abstract][Full Text] [Related]
15. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial.
Dalton JT; Barnette KG; Bohl CE; Hancock ML; Rodriguez D; Dodson ST; Morton RA; Steiner MS
J Cachexia Sarcopenia Muscle; 2011 Sep; 2(3):153-161. PubMed ID: 22031847
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia.
Murphy KT; Chee A; Trieu J; Naim T; Lynch GS
Int J Cancer; 2013 Sep; 133(5):1234-46. PubMed ID: 23436228
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
18. Babao Dan Alleviates Cancer Cachexia in Mice Via Inhibiting IL-6/STAT3 Signaling Pathway.
Qiu Z; Wo D; Zhong X; Chen J; Ma E; He J; Peng J; Zhu W; Ren DN
Integr Cancer Ther; 2023; 22():15347354231168369. PubMed ID: 37077153
[TBL] [Abstract][Full Text] [Related]
19. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
Crawford J; Prado CM; Johnston MA; Gralla RJ; Taylor RP; Hancock ML; Dalton JT
Curr Oncol Rep; 2016 Jun; 18(6):37. PubMed ID: 27138015
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice.
Niu M; Song S; Su Z; Wei L; Li L; Pu W; Zhao C; Ding Y; Wang J; Cao W; Gao Q; Wang H
Br J Pharmacol; 2021 Nov; 178(22):4485-4500. PubMed ID: 34265073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
